imugene (asx:imu) doses first patient in iv arm of phase 1 oncarlytics trial targeting solid cancers
Published 3 months ago • 638 plays • Length 4:14Download video MP4
Download video MP3
Similar videos
-
5:00
imugene doses first patient in intravenous monotherapy arm of phase 1 clinical trial
-
5:00
imugene doses first patient in intravenous monotherapy arm of phase 1 clinical trial
-
6:40
imugene doses first patient in vaxinia phase 1 trial
-
3:04
imugene progresses oncarlytics solid tumour trial to combination arm
-
9:34
imugene (asx: imu) – first patient dosed in checkvacc phase 1 trials
-
26:23
imugene (asx:imu) presentation, nwr virtual healthcare conference
-
5:20
imugene welcomes dosing of first patient in nextherizon phase 2 clinical trial
-
4:00
imugene doses first patient in pd1-vaxx combination trial
-
6:16
imugene's new cancer therapy cd19 (oncarlytics) considered the 'holy grail'
-
5:40
imugene secures ind approval for first-in-class oncarlytics trial
-
4:03
imugene doses first patient in phase-two study of cancer vaccine
-
5:15
imugene thrilled as first patients dosed in vaxinia mast combination study
-
7:40
imugene limited (asx: imu) emergence 2024: presentation by leslie chong, managing director and ceo
-
18:46
imugene (asx: imu) presentation | nwr virtual healthcare conference
-
9:16
imugene ceo leslie chong presents at wholesale investor's virtual showcase july 2020
-
13:15
imugene ltd (asx:imu) investor presentation 2017
-
4:30
imugene md shares with juststocks plans for phase 1 oncarlytics combination study
-
11:25
imugene bringing effective new treatments and options to cancer patients